The U.S. Food and Drug Administration (FDA) has agreed to review Pharming’s application to get Ruconest (conestat alfa) approved for the routine prevention of swelling attacks caused by hereditary angioedema (HAE). The therapy already is approved for the acute treatment of swelling attacks in adults and adolescents with…
News
Recent Posts
- Lonvo-z gene-editing therapy lowers HAE attacks by 87% in Phase 3 trial
- In life with angioedema, sometimes we just aren’t prepared to ‘take the win’
- HAE Day supporters hope to end years of diagnostic uncertainty
- From foot races to lit landmarks, HAE Day on May 16 aims to raise awareness
- Combined use of deucrictibant formulations in HAE expected to be safe